Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.

Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E.

J Surg Res. 2010 May 15;160(2):179-83. doi: 10.1016/j.jss.2009.05.031. Epub 2009 Jun 17.

PMID:
19765726
2.

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.

Endocr J. 2011;58(5):381-93. Epub 2011 Apr 15.

3.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

4.

Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.

Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V.

Endocr Pathol. 2010 Jun;21(2):73-9. doi: 10.1007/s12022-009-9101-3.

PMID:
20012784
5.

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.

Tobiás B, Halászlaki C, Balla B, Kósa JP, Árvai K, Horváth P, Takács I, Nagy Z, Horváth E, Horányi J, Járay B, Székely E, Székely T, Győri G, Putz Z, Dank M, Valkusz Z, Vasas B, Iványi B, Lakatos P.

Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.

PMID:
26259532
6.

NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.

Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE.

Cancer. 2016 Apr 1;122(7):1097-107. doi: 10.1002/cncr.29887. Epub 2016 Jan 19.

7.

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE.

Am J Surg Pathol. 2006 Feb;30(2):216-22.

PMID:
16434896
8.

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6.

PMID:
16181240
9.

Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.

Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, Dinis J, Catarino A, Pereira T, Leite V.

Oncol Rep. 2007 Oct;18(4):917-26.

PMID:
17786355
10.

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.

Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.

11.

Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.

Moses W, Weng J, Kebebew E.

Thyroid. 2011 Apr;21(4):367-71. doi: 10.1089/thy.2010.0256. Epub 2010 Dec 29.

12.

Radiation induced thyroid cancer: fundamental and applied aspects.

Tronko M, Bogdanova T, Voskoboynyk L, Zurnadzhy L, Shpak V, Gulak L.

Exp Oncol. 2010 Sep;32(3):200-4.

PMID:
21403618
13.

The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A.

Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1.

14.

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E.

Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9.

PMID:
16402937
15.

RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.

Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A, Pacini F.

J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6.

PMID:
11443191
16.

Oncogenic alterations in papillary thyroid cancers of young patients.

Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A.

Thyroid. 2012 Jan;22(1):17-26. doi: 10.1089/thy.2011.0215. Epub 2011 Dec 7.

PMID:
22150560
17.

[Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].

Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS.

Vopr Onkol. 2006;52(2):145-9. Russian.

PMID:
17195637
18.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
19.

Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.

Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA.

Mod Pathol. 2010 Sep;23(9):1191-200. doi: 10.1038/modpathol.2010.112. Epub 2010 Jun 4.

20.

Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.

Brzeziańska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Włoch J, Lewiński A.

Mutat Res. 2006 Jul 25;599(1-2):26-35. Epub 2006 Feb 17.

PMID:
16483615

Supplemental Content

Support Center